$KTRANot financial advice.
NASDAQ:KTRA weekly chart looks like wants to break this downtrend line.. Inside candle for those familiar with the STRAT
Like and subscribe for more ideas.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−4.0797USD
−14.65 MUSD
0.00USD
55.36 M
About Kintara Therapeutics, Inc.
Sector
Industry
CEO
Robert E. Hoffman
Website
Headquarters
San Diego
Founded
2009
FIGI
BBG001J7N7K8
Kintara Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of new cancer therapies. Its product pipeline includes VAL-083 and REM-001. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.
KTRA oversold! Price target and stop lossKintara Therapeutics, Inc. (KTRA) oversold on the daily!
Based on support and resistance we have:
Price target: 2.60usd
Stop loss: 0.58usd
$KTRA price holding on strong support$KTRA price is holding on strong support. Waiting to see for a bounce
KTRA Bullish SetupShort term MAs are crossing the longer term MAs and the MACD is rising. I like yesterday's candle retesting the 0 fib level m testing the .38 level and closing above the .23 fib level.
Looking for a break of 1.76 to enter for a swing trade.
target: 1.92 in the short term.
KTRA 2x Phase two drugs data due soon.100m shelf popped out of the blue, now in effect. Phase two data is due and looks to be positive. Cap is under 60m. Seems very undervalued here. The shelf is strange because the CEO has stated that they had enough cash to get through Q4/21, so why the offering now?
Technical + Potential Catalyst. Low risk high rewardBroke out of a trend line and retested 1.30, looks to be heading towards 1.80 based on the sideways pattern. If it breaks out of sideways pattern there may be more upside.
Stop loss can be somewhere below the sideways pattern.
Kintara will be presenting in H.C. Wainwright Bioconnect 2021 Virtual Co
Kintara Therapeutics, Inc. On Breakout Alert Kintara Therapeutics, Inc. is a clinical and biopharmaceutical company, which focuses on the development and commercialization of new cancer therapies. It pipeline includes the VAL-083. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headqu
See all ideas
Frequently Asked Questions
The current price of KTRA is 0.1867 USD — it has decreased by −2.35% in the past 24 hours. Watch Kintara Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Kintara Therapeutics, Inc. stocks are traded under the ticker KTRA.
KTRA stock has fallen by −11.05% compared to the previous week, the month change is a −1.74% fall, over the last year Kintara Therapeutics, Inc. has showed a −95.20% decrease.
KTRA reached its all-time high on Feb 27, 2013 with the price of 6,800.0000 USD, and its all-time low was 0.0810 USD and was reached on Mar 12, 2024. View more price dynamics on KTRA chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
KTRA stock is 5.86% volatile and has beta coefficient of −2.84. Track Kintara Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Kintara Therapeutics, Inc. there?
Today Kintara Therapeutics, Inc. has the market capitalization of 10.59 M, it has increased by 20.44% over the last week.
Yes, you can track Kintara Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Kintara Therapeutics, Inc. is going to release the next earnings report on Nov 11, 2024. Keep track of upcoming events with our Earnings Calendar.
KTRA earnings for the last quarter are −0.05 USD per share, whereas the estimation was −0.25 USD resulting in a 80.00% surprise. The estimated earnings for the next quarter are −0.26 USD per share. See more details about Kintara Therapeutics, Inc. earnings.
KTRA net income for the last quarter is −2.01 M USD, while the quarter before that showed −1.02 M USD of net income which accounts for −96.58% change. Track more Kintara Therapeutics, Inc. financial stats to get the full picture.
No, KTRA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Oct 4, 2024, the company has 17.00 employees. See our rating of the largest employees — is Kintara Therapeutics, Inc. on this list?
Like other stocks, KTRA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Kintara Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Kintara Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Kintara Therapeutics, Inc. stock shows the sell signal. See more of Kintara Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.